A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of NBI-827104 in Subjects with Essential Tremor
Latest Information Update: 12 Sep 2023
Price :
$35 *
At a glance
- Drugs Apinocaltamide (Primary)
- Indications Essential tremor
- Focus Adverse reactions; Therapeutic Use
- Sponsors Neurocrine Biosciences
- 08 Jul 2022 Status changed from recruiting to completed.
- 13 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Jun 2022.
- 13 Apr 2022 Planned primary completion date changed from 1 Mar 2022 to 1 May 2022.